LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS GuidanceBusiness Wire • 05/06/26
Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep ApneaBusiness Wire • 04/20/26
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep ApneaBusiness Wire • 03/19/26
Down 7.2% in 4 Weeks, Here's Why You Should You Buy the Dip in LivaNova (LIVN)Zacks Investment Research • 03/13/26
LivaNova (LIVN) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 02/25/26
LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 GuidanceBusiness Wire • 02/25/26
LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/14/26
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual MeetingBusiness Wire • 12/03/25
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep ApneaBusiness Wire • 12/02/25
LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid ServicesBusiness Wire • 11/24/25
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor DayBusiness Wire • 11/12/25